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Multifunctional drug anisomycin was subjected to forced degradation in accordance with International 
Conference on Harmonisation (ICH) guidelines for the first time. The drug was exposed to the 
recommended stress conditions of hydrolysis (acidic, alkaline and neutral), oxidation, thermal stress 
and photolysis, in order to investigate its stability. Optimized LC–MS/MS method was validated as 
recommended by ICH Q2(R1) guideline with respect to the specificity, accuracy, precision, limits 
of detection and quantitation, linearity and robustness. Anisomycin exhibited high instability under 
alkaline and thermal (neutral hydrolysis) conditions. It showed moderate stability under acidic, neutral, 
oxidative, thermal (acidic hydrolysis) and photolytic conditions, with the lowest degradation level 
observed in the case of light and oxidation stress. Formation of the same degradation product, identified 
as deacetylanisomycin, was observed under all applied stress conditions.
Keywords: Anisomycin/forced degradation. Stability-indicating. LC–MS/MS/validation. 
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INTRODUCTION
Anisomycin,  also known as f lagecidin,  is 
a pyrrolidine antibiotic isolated from two species 
of Streptomyces, identified as S. griseolus and S. 
roseochromogenes (Sobin, Tanner, 1954). Anisomycin 
has an empirical formula of C14H19NO4 and its IUPAC 
name is 2-p-methoxyphenylmethyl-3-acetoxy-4-
hydroxypyrrolidine. In the previous studies it was shown 
that anisomycin exhibits multifunctional properties, 
however, it is still not clinically used. Anisomycin is a 
well-known inhibitor of protein synthesis (Grollman, 
1967; Barbacid, Vazquez, 1974). Its effects on memory and 
influence on behavior have been widely reported (Cohen et 
al., 2006; Pena et al., 2014; Lopez et al., 2015). Therefore, 
anisomycin is proposed as a potential psychiatric drug. 
Namely, in some studies on animals it was shown that 
it affects protein synthesis in amygdala, a part of brain 
that influences memory. As a result, anisomycin inhibits 
the consolidation of new memories and can even cause 
amnesia (Nader, Schafe, Le Doux, 2000; Hardt, Wang, 
Nader, 2009; Ryan et al., 2015). Furthermore, previous 
findings have indicated that anisomycin may function as 
an immunosuppressant in low doses, and it has possible 
application in the treatment of some autoimmune diseases 
and the inhibition of the transplantation rejection (Xing et 
al., 2008; Sun et al., 2013). In the future, this drug might 
possibly be used in therapies as an antitumor agent since 
it was shown that anisomycin suppresses malignant tumor 
cell growth (Curtin, Cotter, 2002; Jin et al., 2013). Also, 
anisomycin possesses herbicidal activity, as well as the 
selective activity against pathogenic protozoa and fungi 
(Reddy, Kumar, Rao, 2005; Zhang et al., 2013). Still, some 
of the mechanisms of its action and additional areas of 
potential usage remain unknown (Macías-Silva, Vázquez-
Victorio, Hernández-Damián, 2010).
It is of great importance to understand the stability of a 
drug molecule, i.e. to know how the quality of a drug varies 
with time under the influence of a variety of environmental 
factors. The International Conference on Harmonisation 
(ICH) guidelines on stability testing of new drug substances 
and products Q1A(R2) and Q1B (ICH, 2003; ICH, 1996) 
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suggest stress studies on a drug to establish its stability 
characteristics. To the best of our knowledge, there are no 
such studies on anisomycin. Liquid chromatography (LC) 
is an analytical technique widely used in the pharmaceutical 
industry for investigation of drug degradation and analysis 
of the degradation products. Anisomycin has been identified 
and analyzed using liquid chromatography, as well as 
ultraviolet (UV), infrared and nuclear magnetic resonance 
spectroscopy, and mass spectrometry (Kirchmeier, Upton, 
1978; LeFevre, Maier, Deng, 1993; Rusanova et al., 2000; 
Abdel-Aal et al., 2011; Tolić et al., 2015; Tolić et al., 2016). 
In our previous papers, liquid chromatography coupled 
to tandem mass spectrometry (LC–MS/MS) was used as 
a comparative method for investigation of anisomycin 
electrochemical degradation in standard solution and in 
urine (Tolić et al., 2015), as well as for determination 
of anisomycin in various tissues and serum (Tolić et al., 
2016). In the later, the method was validated according to 
FDA guidelines for bioanalytical method validation (FDA, 
2001). However, to the best of our knowledge, there are no 
stability-indicating LC–UV nor LC–MS/MS based methods 
validated according to ICH Q2(R1) guideline (ICH, 1994) 
used for investigation of anisomycin. Therefore, the aim 
of this work was to investigate degradation behavior of 
anisomycin in order to understand the stability of the drug 
molecule and to identify the degradation products. This was 
accomplished by exposing the drug to ICH recommended 
stress conditions of hydrolysis, oxidation, thermal stress and 
photolysis, and by analyzing the samples using optimized 
and validated stability-indicating LC–MS/MS method. 
MATERIAL AND METHODS
Chemicals and reagents
The anisomycin standard (purity ≥ 98%) was 
obtained from Fermentek (Jerusalem, Israel). HPLC 
grade methanol, acetonitrile and acetic acid were supplied 
by Sigma-Aldrich (St. Louis, MO, USA). All analytical 
grade reagents (35% hydrochloric acid, sodium hydroxide 
and 30% hydrogen peroxide) were purchased from Lach-
Ner (Neratovica, Czech Republic). Deionized water was 
obtained by passing the distilled water through a GenPure 
ultrapure water system (TKA, Niederelbert, Germany).
Preparation of standard solutions
The stock standard solution was prepared at the 
concentration of 100 μg mL–1 by dissolving 1.0 mg of 
anisomycin in 10 mL of methanol. The working standard 
solutions were prepared by diluting the stock standard 
solution with methanol to the appropriate concentrations. 
In the case of acidic hydrolysis, acetonitrile was used 
instead of methanol. Namely, alcohols should not be used 
as solvents under acidic conditions due to their reactivity 
(Alsante et al., 2007). 
Liquid chromatography
Previously developed LC–MS/MS method for 
identification and quantification of anisomycin (Tolić et 
al., 2015; Tolić et al., 2016) was slightly changed and 
adjusted in order to achieve chromatographic separation 
of anisomycin and its degradation product. Liquid 
chromatography was performed using a Dionex UltiMate 
3000® LC system (Thermo Fisher Scientific, Waltham, 
MA, USA). Surveyor photo diode array (PDA) detector 
(Thermo Fisher Scientific) was used in LC–UV analysis. 
It was operated at the wavelengths of 225 nm and 275 nm, 
the two absorption maxima of anisomycin (Figure 1A). 
A reverse-phase Zorbax Eclipse® XDB-C18 column, 
75 mm × 4.6 mm i.d. and 3.5 µm particle size (Agilent 
Technologies, Santa Clara, CA, USA), was used for 
separation of the compounds. Column temperature was 
maintained at 35 °C. In front of the separation column, 
the pre-column was installed: 12.5 mm × 4.6 mm i.d. and 
5 µm particle size (Agilent Technologies). The mobile 
phase consisted of deionized water, methanol and 10% 
acetic acid (79:20:1, v/v/v). The isocratic flow rate of the 
mobile phase was 0.9 mL min–1. An aliquot of 10 µL of 
the solution was injected into the LC system.
Mass spectrometry
Mass spectra were obtained by LTQ XL (Thermo 
Fisher Scientific) linear ion trap mass spectrometer. 
Electrospray was used as the ionization technique in 
the positive mode. Fragmentation reaction of the most 
abundant ion in the MS spectrum (m/z 266, Figure 1B) 
to the most intensive fragment ion (m/z 206, Figure 1C) 
was used for quantification of anisomycin in the selected 
reaction monitoring (SRM) mode. The MSn study of 
anisomycin was performed using the following source 
working parameters: source voltage (5.0 kV), capillary 
temperature (350 °C) and sheath gas (47 au, i.e. 47 
arbitrary units, in the 0–100 range defined by the LTQ XL 
system). Helium was used as a collision gas.
Method validation
T h e  L C – M S / M S  m e t h o d  w a s  v a l i d a t e d 
in accordance with ICH Q2(R1) guideline (ICH, 
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1994) for the validation of analytical procedures. 
Investigated validation characteristics of the method 
were: specificity, accuracy, precision, limit of detection, 
limit of quantitation, linearity, range, and robustness. 
The specificity is the ability of an analytical method to 
reliably assess the analyte in the presence of the matrix 
components, impurities, degradation products, etc. It was 
determined by subjecting the drug to stress under various 
conditions (acidic, alkaline, neutral, oxidative, thermal 
and photolytic) followed by evaluation of anisomycin 
separation from the degradation products (Rao et al., 
2011; Patel et al., 2015; Runje et al., 2016). Blank and 
standard solution samples were analyzed simultaneously 
with the stressed sample.
The accuracy of an analytical procedure expresses 
the closeness of agreement between the value which 
is accepted as a true value and the value found. It was 
determined by analyzing the known concentration of 
drug in spiked stressed sample (acidic hydrolysis), 
from the difference between peak areas of fortified and 
unfortified stressed samples (Ramesh, Rao, Rao, 2014; 
Patel et al., 2015). The experiment was performed in 
triplicate at three concentration levels (700, 1000 and 
1300 ng mL–1), covering the range 70–130% of the test 
concentration (ICH, 1994). The accuracy was expressed as 
the percentage recovery obtained by comparing calculated 
spiked concentration and true value.
The precision of an analytical procedure expresses 
the closeness of agreement between a series of 
measurements obtained from multiple sampling of the 
same homogeneous sample. It was determined in the same 
experiments as the accuracy of an analytical procedure. 
The intra- and interday precision were established by 
analyzing every spiked stressed sample three times on the 
same day and on three consecutive days, respectively. The 
precision was expressed as the relative standard deviation 
(RSD) of a series of measurements.
Limit of detection (LOD) and limit of quantitation 
(LOQ) were determined as concentrations of the analyte 
that would produce a signal to noise ratio of 3:1 and 10:1, 
respectively. These values were determined by injecting 
the series of anisomycin solutions in the concentration 
range 1–50 ng mL–1 (Luo et al., 2015; Runje et al., 2016).
The linearity of an analytical procedure is its ability 
(within a given range) to obtain results which are directly 
proportional to the concentration of analyte in the sample. 
The range of an analytical procedure is the interval 
between the upper and lower concentration of analyte in 
the sample for which it has been demonstrated that the 
analytical procedure has a suitable level of precision, 
accuracy and linearity. To establish linearity and range of 
the method, stock standard solution of anisomycin was 
diluted to seven concentration levels in the range 700–
1300 ng mL–1. The analysis was carried out in triplicate 
(Ramesh, Rao, Rao, 2014). The peak areas were plotted 
against the corresponding concentrations to obtain the 
calibration graph and the data were subjected to statistical 
analysis using a linear regression.
The robustness of an analytical procedure is a 
measure of its capacity to remain unaffected by small, but 
deliberate variations in method parameters. It provides an 
indication of the method reliability during normal usage. 
Variations in the following method parameters were tested: 
the mobile phase composition (percentage of the organic 
solvent, 20 ± 5%), the flow rate (0.8–1.0 mL min–1) and 
the pH value (3.3 ± 0.1), as well as the column temperature 
FIGURE 1 - Anisomycin spectra: A) UV spectrum, B) mass spectrum, C) MS/MS spectrum of the protonated molecule, and 
D) proposed fragmentation pathway of anisomycin.
Lj. Tolić, S. Grujić, M. Laušević
Braz. J. Pharm. Sci. 2018;54(2):e17491Page 4 / 12
(35 ± 5 °C). The experiment was performed in triplicate at 
three concentration levels (700, 1000 and 1300 ng mL–1).
Forced degradation
Forced degradation study of anisomycin was 
performed in accordance with ICH guidelines on stability 
testing of new drug substances and products (ICH, 2003; 
ICH, 1996). Experiments were carried out in order to 
assess the effect of acidic, alkaline and neutral hydrolysis, 
oxidation, thermal stress, and light on anisomycin stability. 
ICH guidelines do not define specific stress conditions 
under which these experiments should be performed, 
as they depend on the compound characteristics. Stress 
conditions in this work were selected based on the 
literature survey (Table I) and adjusted to anisomycin 
properties.
Generally, the objective of forced degradation is to 
induce 5–20% degradation of the active pharmaceutical 
ingredient (Baertschi, 2005). In this study, some 
degradation experiments were performed over a longer 
period of time than suggested and even until complete 
anisomycin degradation. In the experiment of acidic 
hydrolysis, 5 mL of 1 M HCl was added to 5 mL of 
anisomycin stock standard solution in acetonitrile at room 
temperature. At predetermined time intervals, aliquots of 
the stressed sample were withdrawn and neutralized with 
the appropriate volume of 1 M NaOH. Acidic hydrolysis 
experiment was monitored up to 30 days. All samples were 
diluted to the expected concentration of 1000 ng mL–1 
prior to LC–MS/MS analysis. They were filtered through 
0.45 µm PVDF (polyvinylidene difluoride) filter acquired 
from Roth (Karlsruhe, Germany) into the autosampler 
vials and analyzed. 
Alkaline hydrolysis of anisomycin was carried out 
by mixing 5 mL of stock standard solution with 5 mL of 
0.1 M NaOH at room temperature. After 20 min and 1 h, 
aliquots of stressed sample were neutralized with the 
TABLE I - Literature survey of various stress conditions for degradation of different drugs
Analyte Acidic hydrolysis
Alkaline 
hydrolysis
Neutral 
hydrolysis Oxidation
Thermal 
degradation Photodegradation Literature
API 0.1 M HCl 0.1 M NaOH / 3% H2O2 60 °C
Metal halide, mercury, 
xenon or UV–B fluorescent 
lamp
WHO, 2005
API
0.1 M HCl, 
40 or 60 °C
0.1 M NaOH, 
40 or 60 °C
H2O, 
40 or 60 °C
3% H2O2, 
25 or 60 °C
60 or 80 °C
Illumination ≥ 1,2·106 lx h, 
UV light ≥ 200 Wh m−2
Blessy et al., 
2014
API
0.1–1 M 
HCl or H2SO4
0.1–1 M NaOH 
or LiOH or KOH
/ 3% H2O2 > 50 °C
Illumination ≥ 1,2·106 lx h, 
UV light ≥ 200 Wh m−2
Alsante et al., 
2007
Abacavir 
sulphate
1 M HCl, 
80 °C
1 M NaOH, 
80 °C
H2O, 
80 °C
3% H2O2, 
6% H2O2, 
1.5 mM AIBN
100 °C UV light (320 nm)
Rao et al., 
2011
Fingolimod 3 M HCl 0.1 M NaOH
H2O, 
80 °C
30% H2O2, 
room t
90 °C
Illumination ≥ 1,2·106 lx h, 
UV light ≥ 200 Wh m−2
Patel et al., 
2015
Nepafenac
0.1 M HCl, 
25 °C
0.1 M NaOH, 
25 °C
/ 30% H2O2, 
25 °C
80 °C
Illumination ≥ 1,2·106 lx h, 
UV light ≥ 200 Wh m−2
Runje et al., 
2016
Zofenopril
1 M HCl, 
80 °C
1 M NaOH, 
80 °C
H2O, 
80 °C
3% H2O2, 
6% H2O2, 
room t
100 °C UV light (320 nm)
Ramesh, Rao, 
Rao, 2014
Ezetimibe
0.1 M HCl, 
80 °C
0.1 M NaOH, 
room t
H2O, 
80 °C
3% H2O2 80 °C 4500 lx
Luo et al., 
2015
Zolpidem 
tartrate
1 M HCl, 
room t
0.1 M NaOH, 
room t
H2O, 
room t
10% H2O2, 
room t
70 °C
Illumination ≥ 1,2·106 lx h, 
UV light ≥ 200 Wh m−2
Malešević et 
al., 2014
Rabeprazole
0.01 M HCl, 
room t
2 M NaOH, 
80 °C
H2O, 
80 °C
3% H2O2, 
room t
80 °C
Illumination ≥ 1,2·106 lx h, 
UV light ≥ 200 Wh m−2
Bhandi et al., 
2016
Atorvastatin 
calcium and 
celecoxib
1 M HCl 
70 °C
1 M NaOH 
70 °C
/ 30% H2O2, 
70 °C
100 °C Direct sunlight
Jadhav, Jamkar, 
Avachat, 2015
API: active pharmaceutical ingredient, WHO: World Health Organization, UV: ultraviolet, AIBN: 2,2’-azobisisobutyronitrile
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appropriate volume of 0.1 M HCl. Neutral hydrolysis was 
performed by adding 5 mL of deionized water to 5 mL of 
anisomycin stock standard solution at room temperature. 
Degradation was monitored for 16 days by analyzing the 
aliquots withdrawn at predetermined time points. 
For oxidative degradation study of anisomycin, 
5 mL of 30% H2O2 was added to 5 mL of stock standard 
solution at room temperature. Anisomycin oxidation was 
monitored up to 30 days. The effect of thermal stress on 
anisomycin stability was estimated in the experiments 
of acidic and neutral hydrolysis performed at 60 °C in a 
water bath for 48 h. 
The photolytic degradation study was done by 
exposing the stock standard solution of the drug to Osram 
Ultra Vitalux® 300 W lamp at a distance of 40 cm for 6 h 
in order to achieve an overall illumination of not less than 
1.2 million lx h and an overall energy of 200 Wh m−2 UV 
light (ICH, 1996) in the photostability chamber. Along 
with the stressed sample, stock standard solution of 
anisomycin was kept in dark under the same conditions 
and for the same period of time to serve as a dark control. 
In every forced degradation experiment, appropriate 
blank sample and anisomycin standard solution were 
simultaneously analyzed with the stressed samples.
RESULTS AND DISCUSSION
MSn study of anisomycin
The mass analysis of the precursor ion (m/z 266.2) 
of the drug produced five fragment ions at m/z 224.1, 
206.1, 188.1, 159.0 and 121.1 (Figure 1C). The proposed 
fragmentation pathway of anisomycin is summarized in 
Figure 1D. It is proposed that the fragment ion m/z 224.1 
is formed by the loss of the acetyl group at the position 
3 of the pyrrolidine ring. In subsequent MS3 studies m/z 
224.1 ion fragmented into four daughter ions m/z 206.1, 
188.1, 159.0 and 121.1. The dominant fragment ion (m/z 
206.1) is probably formed by the loss of the hydroxyl 
group at the same position of the pyrrolidine ring. It is 
proposed that double bond is then formed in the ring. 
Furthermore, ion m/z 206.1 is fragmented into three 
fragment ions m/z 188.1, 159.0 and 121.1. The product 
ion m/z 188.1 is possibly formed by the loss of another 
hydroxyl group at the position 4 of the pyrrolidine ring, 
and formation of another double bond. Finally, ion m/z 
188.1 is fragmented into ions m/z 159.0 and 121.1. It 
is proposed that daughter ion m/z 159.0 is formed by 
the loss of the pyrrolidine ring moiety and the ion m/z 
121.1 is formed by the loss of the methoxy group of the 
benzene ring. 
Method validation
Specificity of the method was determined by 
assessing the anisomycin in the presence of stress 
reagents and degradation products. It was observed that 
anisomycin was well separated from its degradation 
product (Figure 2C), which unambiguously confirms the 
specificity of the method. Chromatogram of the blank 
sample (Figure 2A) did not show any interference at the 
retention time of the drug or its degradation product. 
The results obtained for accuracy and precision 
at the tested concentration levels (Table II) showed 
that the method is accurate and reliable. The recovery 
of anisomycin in the presence of stress reagents and 
degradation product ranged from 98.8% to 100.5%. RSD 
values of intra- (0.3%–1.6% ) and interday (2.8%–4.1% ) 
precision indicate good repeatability of the method.
The LOD and LOQ values were found to be 
2.5 ng mL–1 and 8.3 ng mL–1, respectively, indicating 
that the method for determination of anisomycin is very 
sensitive.
Good l ineari ty was observed in the tested 
concentration range 700–1300 ng mL–1. The correlation 
coefficient (R2) was determined to be 0.9961. 
Robustness of the method was determined by 
changing the percentage of organic solvent in the mobile 
phase, flow rate and pH value of the mobile phase, as well 
as the column temperature. Obtained RSD values were in 
the range 2.1–7.4% (Table III). It can be concluded that 
small and insignificant changes in the assay values were 
observed and that the method was robust.
Degradation behavior of anisomycin
Stressed samples obtained under various conditions 
were directly injected into mass spectrometer in order to 
identify present ions, i.e. degradation products. Degradation 
of anisomycin, to a different extent, was observed under 
all tested stress conditions. Only one degradation product 
was detected in all experiments (Figure S1, Supplementary 
information session and Figure 2). As it can be seen in 
Figure S1 as well as in Figure 2C, the dominant ion in 
mass spectra of the stressed samples, besides anisomycin 
(m/z 266), is the ion with m/z value 224. This compound 
was previously identified as deacetylanisomycin (Reddy, 
Rao, 2011; Tolić et al., 2015). Mass and MS/MS spectra 
of deacetylanisomycin are presented in Figure 3. In MS2 
analysis, deacetylanisomycin ion is fragmented into four 
daughter ions with m/z values of 206.1, 188.1, 159.0 and 
121.1 (Figure 3B). Fragmentation reaction of the precursor 
ion (m/z 224) to the most intensive fragment ion (m/z 188) 
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was selected for determination of deacetylanisomycin in 
LC–MS/MS analysis. Proposed fragmentation pathway of 
deacetylanisomycin and structures of its fragment ions are 
presented in Figure 3C. This degradation product is most 
probably formed by deacetylation of anisomycin pyrrolidine 
ring (Figure 3D). It is interesting to point out that the removal 
of the acetyl group significantly reduces anisomycin activity 
(Grollman, 1967). After mass analysis of the stressed 
FIGURE 2 - Mass spectra, LC–UV and LC–MS/MS chromatograms of: A) blank sample, B) standard solution of anisomycin (ANI), 
C) stressed sample (neutral hydrolysis) with degradation product (DP).
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samples, they were analyzed using the validated method. 
Typical SRM chromatograms are presented in Figure 4. 
Investigation of anisomycin degradation behavior 
showed that, under alkaline and thermal (neutral) 
conditions, anisomycin exhibited high instability, while 
it was moderately stable under acidic, neutral, oxidative, 
thermal (acidic) and photolytic conditions (Table IV). 
Moreover, the lowest degradation level was observed in 
the case of light and oxidation stress. Degradation of the 
drug under different stress conditions and formation of its 
degradation product over time are shown in Figure 5. The 
amount of deacetylanisomycin was determined relative 
to anisomycin amount under the assumption that it was a 
single degradation product. 
The most rapid degradation was achieved under 
alkaline conditions. After just one hour, anisomycin was 
completely degraded (Table IV, Figure 5B). The heat 
seems to accelerate the drug degradation process. At room 
TABLE II - Accuracy (n = 3) and precision (n = 9) of the method
Concentration 
(ng mL–1)
Accuracy Intraday precision Interday precision
Calculated spiked 
concentration ± SD 
(ng mL–1); 
RSD (%)
Recovery (%)
Measured 
concentration ± SD 
(ng mL–1); 
RSD (%)
Measured 
concentration ± SD 
(ng mL–1); 
RSD (%)
700 691.5 ± 33.4; 4.8 98.8 701.4 ± 1.9; 0.3 682.0 ± 22.4; 3.3
1000 997.4 ± 13.9; 1.4 99.7 990.2 ± 13.9; 1.4 1013.3 ± 41.3; 4.1
1300 1306.3 ± 64.0; 4.9 100.5 1315.1 ± 21.3; 1.6 1334.6 ± 36.9; 2.8
TABLE III - Robustness of the method
Concentration 
(ng mL–1)
Organic solvent Flow rate pH value Column temperature
RSD (%)
700 7.2 6.2 5.8 2.1
1000 7.0 5.1 5.5 2.2
1300 7.4 5.6 6.4 2.4
FIGURE 3 - Deacetylanisomycins’: A) mass spectrum, B) MS/MS spectrum, C) proposed fragmentation pathway, D) proposed 
formation by anisomycin degradation.
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FIGURE 4 - SRM chromatograms of anisomycin (ANI) and its degradation product (DP): A) acidic hydrolysis, B) alkaline 
hydrolysis, C) blank, D) anisomycin standard solution.
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FIGURE 5 - Anisomycin (○) degradation and degradation product (▼) formation under different stress conditions: A) acidic 
hydrolysis, B) alkaline hydrolysis, C) neutral hydrolysis, D) oxidation, E) thermal degradation (acidic hydrolysis), F) thermal 
degradation (neutral hydrolysis), G) photolysis.
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TABLE IV - Degradation percent of anisomycin under different stress conditions
Stress conditions Time (h)
Expected 
concentration 
(ng mL–1)
Found 
concentration 
(ng mL–1)
Degradation 
(%)
Acidic 24 1000 778.7 22.1
Alkaline 1 1000 0 100.0
Neutral 24 1000 656.0 34.4
Oxidative 24 1000 843.4 15.7
Thermal (acidic) 24 1000 645.6 35.4
(neutral) 24 1000 67.8 93.2
Photolytic 6 1000 832.1 16.8
temperature, it takes one month for anisomycin to be 
degraded by 77.7% in the presence of acid (Figure 5A). 
When the temperature is raised to 60 °C, the same 
degradation level is achieved after 48 h (Figure 5E). This 
phenomenon is even more pronounced under neutral 
conditions. It took 15 days for drug to be completely 
degraded at room temperature (Figure 5C), whereas at 60 °C 
anisomycin was completely degraded after 48 h (Figure 5F).
In the presence of oxidizing reagent, the drug was 
moderately stable. After 30 days of being exposed to 
30% H2O2, anisomycin degraded to 28.2% of the initial 
amount (Figure 5D). As for the exposure to light source 
recommended by ICH guideline, anisomycin remained 
rather stable. After the illumination period of one hour, 
15.6% of the drug degraded and in the next five hours no 
significant degradation was observed (Figure 5G).
CONCLUSIONS
Stability of anisomycin was examined by performing 
forced degradation study that includes investigation of 
susceptibility of the drug to hydrolysis (acidic, alkaline 
and neutral), oxidation, light and thermal stress, in 
accordance with ICH Q1A(R2) and Q1B guidelines. 
The simple and rapid stability-indicating LC–UV and 
LC–MS/MS methods were used for investigation of the 
drug degradation and identification of the degradation 
product. The optimized LC–MS/MS method was validated 
according to ICH Q2(R1) guidelines and it was found 
to be accurate, precise, sensitive, linear and robust. The 
stability-indicating method also exhibited high specificity, 
as it was able to separate anisomycin from its degradation 
product. It was shown that anisomycin was highly unstable 
under alkaline and thermal (neutral) conditions, while it 
was moderately stable under acidic, neutral, oxidative, 
thermal (acidic) and photolytic conditions. The lowest 
degradation level of anisomycin was observed in the case 
of light and oxidation stress. The same degradation product 
was formed under all applied conditions. It was identified 
as deacetylanisomycin, compound that has significantly 
reduced activity compared to anisomycin.
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